MRI EVALUATION OP SOLITARY BRAIN METASTASES WITH TRIPLE-DOSE GADOTERIDOL - COMPARISON WITH CONTRAST-ENHANCED CT AND CONVENTIONAL-DOSE GADOPENTETATE DIMEGLUMINE MRI STUDIES IN THE SAME PATIENTS

The purpose of this investigation was to compare the sensitivity and safety of high dose gadoteridol (ProHance) with routine dose gadopentetate dimeglumine (Magnevist) in the detection of intracranial metastases on magnetic resonance imaging (MRI) when a solitary intracranial lesion was detected on contrast-enhanced cranial computed tomography (CT). Four patients, each with a solitary intracranial metastasis demonstrated on contrast-enhanced CT were studied prospectively with both 0.3 mmol/kg gadoteridol and 0.1 mmol/kg gadopentetate dimeglumine. Images were acquired before and immediately following contrast administration. Both of the MR studies were performed between two and six days of each other and within 1 wk of the cranial CT. Scan parameters and injection rates were identical on both occasions. Patient monitoring for the gadoteridol study included physical examination, vital signs and laboratory tests at several pre-determined times. Eighteen total metastases were demonstrated on MRI compared to the four on CT. Seven were visualized on the unenhanced MR images, nine on the scans using gadopentetate dimeglumine, and all eighteen on the scans using gadoteridol. Additional lesions were seen on the gadoteridol images in all four patients. No adverse events attributable to contrast media occurred. No significant changes in vital signs or laboratory values occurred.